Psychedelic therapies could someday help treat a range of conditions ranging from alcoholism to Alzheimer’s disease and from long COVID to chronic Lyme disease.

Patients that experience seizure clusters secondary to conditions such as Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex could benefit from the concomitant use of cannabinol (CBD) and diazepam nasal spray, as the former does not significantly impact the latter’s safety or efficacy, according to a recently published study in Epilepsy & Behavior. Cannabinol, in the form of…

A new subpopulation of specialized astrocytes with glutamatergic gliotransmission was discovered, according to a study published in Nature.1 These astrocytes are localized to distinct anatomical locations in the brain and contain a molecular signature that contains glutamate exocytosis machinery, including vesicular glutamate transporter 1 (VGLUT1), similar to that seen in the synapses of neurons. Swiss…

In a novel discovery, Stanford University researchers found that endocannabinoid (eCB) release and synaptic plasticity appear to be mediated by post-synaptic synucleins and SNAREs. The finding, which was published in Nature Neuroscience, warrants future study as synucleins play an integral role in the brain—both in healthy aging and the development of neurodegenerative diseases like Parkinson’s…

A team of researchers from NYU Grossman School of Medicine discover a novel mechanism of action for how cannabidiol (CBD) reduces seizures in treatment-resistant forms of pediatric epilepsy, according to a study published in Neuron. The findings were discovered via in vivo mouse models and have yet to be confirmed through studies involving human subjects.…

Bonni Goldstein, MD, presents at CannMed 23 on treating pediatric refractory epilepsy with full-spectrum medical cannabis.